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Background: Malaria and HIV co-infection adversely impact the outcome of both diseases and previous studies
have mostly focused on falciparum malaria. Plasmodium vivax contributes to almost half of the malaria cases in
India, but the disease burden of HIV and P. vivax co-infection is unclear.
Methods: HIV-infected subjects (n=460) were randomly selected from the 4,611 individuals seen at a Voluntary
Counseling and Testing Center in Chennai, India between Jan 2 to Dec 31 2008. Malaria testing was performed on
stored plasma samples by nested PCR using both genus-specific and species-specific primers and
immunochromatography-based rapid diagnostic test for detecting antibodies against Plasmodium falciparum and P.
vivax.
Results: Recent malaria co-infection, defined by the presence of antibodies, was detected in 9.8% (45/460)
participants. Plasmodium vivax accounted for majority of the infections (60%) followed by P. falciparum (27%) and
mixed infections (13%). Individuals with HIV and malaria co-infection were more likely to be men (p=0.01). Between
those with and without malaria, there was no difference in age (p=0.14), CD4+ T-cell counts (p=0.19) or proportion
CD4+ T-cell below 200/mL (p=0.51).
Conclusions: Retrospective testing of stored plasma samples for malaria antibodies can facilitate identification of
populations with high rates of co-infection, and in this southern India HIV-infected cohort there was a considerable
burden of malaria co-infection, predominantly due to P. vivax. However, the rate of P. falciparum infection was more
than 6-fold higher among HIV-infected individuals than what would be expected in the general population in the
region. Interestingly, individuals co-infected with malaria and HIV were not more likely to be immunosuppressed
than individuals with HIV infection alone.
Keywords: Plasmodium vivax, Plasmodium falciparum, Malaria, HIV, Co-infection, Malaria antibody, Retrospective
testBackground
HIV, a sexually or parenterally transmitted viral infec-
tion, and malaria, a mosquito-borne parasitic disease,
are two disparate and deadly diseases that are often
brought together by overlapping geographic distribu-
tions. When HIV and malaria co-infection occur in the
same individual, both diseases are adversely impacted.
HIV-infected individuals are at increased risk of: acquir-
ing malaria [1] developing severe malarial disease [2,3],
recrudescing malaria symptoms [4], and experiencing* Correspondence: abharti@ucsd.edu
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reproduction in any medium, provided the ortreatment failure of malaria [5]. Additionally, acute mal-
aria is associated with an increase in HIV viral load [6]
and a steeper decline in CD4 cell count [7], and these
viral load and CD4 count changes can take several weeks
to recover after successful malaria therapy [6]. These
interactions may facilitate spread of both diseases [8].
These observations have largely been made in the setting
of HIV co-infection with Plasmodium falciparum in
sub-Saharan Africa. Much less is known whether Plas-
modium vivax has similar interactions with HIV. There-
fore, this study was conducted to: i) determine the
prevalence and risk factors of malaria co-infection in a
cohort of HIV-infected individuals in southern India, atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evaluate the strategy of using stored specimens for quick




The subjects were randomly selected (10%) from the
4,611 HIV-1 positive individuals seen at the Voluntary
Counseling and Testing center of Y. R. Gaitonde Center
for AIDS Research and Education (YRGCARE) between
Jan 2, 2008 and December 31, 2008. They were all newly
diagnosed with HIV-1 infection and were not receiving
antiretroviral therapy. The study was approved by the
ethics boards of the University of California San Diego,
YRGCARE, and the Indian Council of Medical Research.
All volunteers provided written informed consent. Blood
samples were processed immediately following collection
and plasma stored in −70°C freezer for a period ranging
from 18 to 24 months before being evaluated in the
current study.
HIV and CD4+ T-cell count
Blood (6 mL) was collected in EDTA tubes (catalog no.
367861, BD, USA) and plasma separated after centrifu-
gation at 2,500 RPM for 12 min. Tests for diagnosing
HIV were either Determine HIV 1/2 test (Abbott La-
boratories), Signal HIV Rapid Test (Span Diagnostics
Ltd., India), or First Response HIV 1–2.0 (PMC Medical
Pvt. Ltd., India). CD4+ T-cell counts were determined
by flow cytometric panLeukogating method (Beckman
Coulter, USA).
Malaria PCR
DNA was extracted from 200 μL of plasma sample using
QIAamp DNA Blood Mini Kit (catalog no. 51106, Qiagen,
USA). Nested PCR was done using both genus-specific
and species-specific primers (Table 1) targeting the Plas-
modium spp. 18S small subunit ribosomal RNA genes
[9,10]. The first PCR was performed in a total volume of
20 μL containing 3 μL of extracted DNA, 17 μL of i-
Master Mix PCR Kit (catalog no. 25201, Intron Biotech-
nology, Korea), and forward and reverse primers (0.2 μM).
The nested species specific PCR was performed in a totalTable 1 Primers for nested PCR of Plasmodium 18S rRNA gen
Species Primer Sequence
Plasmodium sp. rPLU5 CCTGTTGTTGCC
rPLU6 TTAAAATTGTTG
P. falciparum rFAL1 TTAAACTGGTTT
rFAL2 ACACAATGAAC
P. vivax rVIV1 CGCTTCTAGCT
rVIV2 ACTTCCAAGCCvolume of 20 μL containing 1 μL of PCR product. DNA,
extracted from plasma of microscopy confirmed malaria
positive (P. falciparum and P. vivax) and malaria negative
individuals, was used as positive and negative control, re-
spectively. To confirm the presence of amplifiable human
DNA, 20% (90/460) samples were randomly selected and
underwent PCR using primers for the human rRNA gene
p53 [11].
Malaria antibody testing
An immunochromatography-based rapid diagnostic test
kit, SD BIOLINE Malaria Pf/Pv Kit (Catalog No. 05FK30I-
IN-02, SD Bio Standard Diagnostics Pvt. Ltd., India), was
used for detecting antibodies (IgG, IgM, IgA) against mer-
ozoite surface protein (MSP) of both P. falciparum and
P. vivax. Each of the 460 plasma samples was tested indi-
vidually for malaria antibodies. Blood smears were not
available for examination by microscopy.
Statistical analyses
Student t-test was used for continuous variables and
Chi-square test for categorical variables (IBM SPSS Sta-
tistics Version 19). Non-parametric test, Mann–Whitney
U test, was used where appropriate. One-way ANOVA
was done to compare characteristics of the 3 malaria
positive subgroups.
Results
Participant ages ranged from 21 to 68 years and 63%
were male. Table 2 shows the demographic characteris-
tics of the study cohort. Plasmodium antibodies were
detected in plasma from 45 of the 460 participants
(9.8%). The majority of the infections were due to P.
vivax (60%) followed by P. falciparum (27%) and mixed
infections (13%). Three-fourths of the co-infected indivi-
duals were in the 30-50 year range, but there was no dif-
ference in average age between those with and without
malaria (38 vs. 40 years, p=0.14), median CD4+ T-cell
counts (222 vs. 244/μL, p=0.19) or proportion CD4+ T-
cell below 200/μL (48% vs. 40%, p=0.51). The co-
infected subjects, however, were more likely to be male
(80% vs. 61%, p=0.01). Further analysis of the malaria
positive groups (P. vivax, P. falciparum, and mixed
infections) did not show any significant difference in thee







Table 2 Demographic characteristics of the study cohort
Malaria Neg Malaria Pos p value
(N=415) (N=45)
Mean age, y (±SD) 38 ± 9 40 ± 9 0.14
Gender (Number (%) men) 253 (61%) 36 (80%) 0.01
CD4+ cell count
Median, (IQR),/μL 222 (89, 403) 244 (140, 571) 0.19
Proportion below 200/μL 48% (175/363) 40% (15/38) 0.51
Plasmodium species
P. vivax 27 (60%)
P. falciparum 12 (27%)
Mixed infections 6 (13%)
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proportion below 200/μL). Parasite DNA was not
detected by PCR in any of the samples. Positive and
negative controls were used with each batch of speci-
mens processed and performed as expected. Amplifiable
human DNA, tested using primers for the p53 gene, was
found in 93% (84/90) of the randomly selected samples.
Discussion
In India, the potential for intersection of malaria and
HIV epidemics is great but data on co-infections are
sparse. Two studies, one conducted in Chennai and the
other in Mumbai, have identified co-infected individuals
in hospital-based settings [12,13]. However, this study is
more representative of the community and is the first
one to demonstrate a high P. vivax co-infection rate.
The majority of the infections in this HIV-infected co-
hort were due to P. vivax (60%), which is similar to that
in the general population in the state of Tamil Nadu
[14]. In contrast, compared to the general population
[15], the co-infected cohort had a lower proportion of P.
vivax (60% vs. 96%); higher proportion of P. falciparum
(27% vs. 4%); and a considerable number of mixed infec-
tions (13%). The higher prevalence of falciparum malaria
in HIV-infected individuals has implications for clinical
management. Incorrect identification of Plasmodium
species can lead to inappropriate malaria treatment be-
cause chloroquine is still the first-line treatment for P.
vivax [16], but would be ineffective for falciparum mal-
aria due to high prevalence of chloroquine resistance
[17].
There was a preponderance of men (80%) with a mean
age of 40 ± 9 years in the co-infected group, which mir-
rors the trend seen in the general population [14]. The
high prevalence of malaria co-infection in men may be
related to occupation and travel that puts them at an
increased risk of being bitten by infected mosquitoes
and needs to be investigated further. Interestingly, this
study did not find an association between lower CD4+T-cell count and malaria co-infection. This is in contrast
to other studies where subclinical and symptomatic fal-
ciparum malaria was more common in HIV-infected
compared with HIV-uninfected individuals and the risk
increased with advancing immunosuppression [1,18,19].
Malaria in this cohort was mainly due to P. vivax and it
is speculated that immunosuppression due to HIV may
not increase the risk of vivax malaria co-infection, but
more studies are needed to confirm this finding.
Malaria diagnosis was made by detection of malaria
antibodies by the SD BIOLINE kit. Although, its sensi-
tivity is much lower than microscopy or nested PCR and
ranges from 47% to 69% [20,21], this method is well sui-
ted to detect malaria prevalence in low endemic areas
[22,23]. The anti-MSP antibodies measured have very
short half-lives (9.8 days) [24] that peak by day 7 and are
cleared by day 28 [25]. In the absence of repeated infec-
tions in a region with unstable malaria transmission, this
suggests that malaria infection in this co-infected group
was recent, probably within a range of 1-4 weeks. Al-
though data on symptoms or malaria treatment history
was not collected, it is presumed that subjects were
asymptomatic as they were seen in a HIV testing center
and not a treatment clinic. No parasite DNA was
detected using PCR-based methods. There could be sev-
eral explanations for this. First, parasite DNA in stored
plasma samples may have degraded. This is unlikely, as
the authors have earlier shown that PCR is able to detect
Plasmodium DNA in serum samples frozen up to
2½ years [26]. The current samples were more recent
(less than 2 years old) and better preserved (stored at
−70°C). Another point supporting specimen integrity is
the presence of amplifiable human DNA in 93% of
selected samples. Second, parasite DNA levels may be
below the detection limit of PCR. Although, the sensitiv-
ity of the nested PCR method is high and ranges from
0.5-1 parasite/μL [27,28], plasma samples can have PCR
yield up to 3-fold lower than whole blood [29]. Another
reason for low parasitaemia levels is the high likelihood
of subclinical infection among the participants. Real-
time PCR may have a higher [30] or similar [21,27] sen-
sitivity compared with nested PCR. Longitudinal data is
lacking to confirm whether some individuals went on to
develop symptomatic malaria or detectable parasite
DNA. Further, tests were done only for P. falciparum
and P. vivax, the two predominant Plasmodium species
in the region and may have missed infections caused by
other spp. like Plasmodium ovale and Plasmodium
malariae although their contribution is unlikely given
the antibody results.
Conclusion
Taken together, although malaria antibody test cannot
be used to make a clinical diagnosis, it is a preferred
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regions with unstable malaria transmission, as in this
study region.
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